Methods of treating SARS-CoV-2 infections
The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.
1. A method of treating COVID-19 in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that has the formula:
wherein:
X is O or S;
R 1 is H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 1-6 arlkyl, aryl, heteroaryl bound through a carbon atom, or heterocycle bound through a carbon atom;
R 2 is H, C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 1-6 arlkyl, aryl, heteroaryl bound through a carbon atom, or heterocycle bound through a carbon atom;
R 3 to R 11 are, independently, H, CN, OH, NO 2 , N(R A ) 2 , halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 thioalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 1-6 arlkyl, aryl, heteroaryl, heterocycle, —OC(O)R A , —C(O)R A , C(O)OR A , —OC(O)N(R A ) 2 , —C(O)N(R A ) 2 , —N(R A )C(O)OR A , —N(R A )C(O)R A , —N(R A )C(O)N(R A ) 2 , —N(R A )S(O) 2 R A , —S(O)OR A , —S(O) 2 OR A , —S(O)N(R A ) 2 , —S(O) 2 N(R A ) 2 , or PO 3 (R A ) 2 ;
each R A is, independently, H, OH, C 1-6 alkyl, C 3-8 cycloalkyl, C 1-6 arlkyl, aryl, heteroaryl, or heterocycle;
or a pharmaceutically acceptable salt, solvate, or isomer thereof; wherein said agent is not tauroursodeoxycholic acid (TUDCA).
2. The method of claim 1 , wherein the agent is administered orally.
3. The method of claim 1 , wherein the agent is administered parenterally.
4. The method of claim 1 , wherein the agent is administered via inhalation.
5. The method of claim 1 , wherein the amount of the agent administered to the subject is up to 5 g/day.
6. The method of claim 1 , wherein the agent is administered in divided doses.
7. The method of claim 1 , wherein the administration results in a reduction in the subject's SARS-CoV-2 viral load.
8. The method of claim 1 , wherein the administration results in an improvement in one or more of the subject's viral infection symptoms.
9. The method of claim 1 , wherein the administration results in an improvement in the subject's clinical status.
10. The method of claim 1 , wherein the subject has or is suspected of having COVID-19.
11. The method of claim 1 , wherein the agent is administered after the subject is presenting a symptom of COVID-19.
12. The method of claim 1 , wherein the agent is administered prior to the subject presenting a symptom of COVID-19.
13. A method of inactivating a SARS-CoV-2 virus comprising contacting the virus with an effective amount of an agent that has the formula:
wherein:
X is O or S;
R 1 is H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 1-6 arlkyl, aryl, heteroaryl bound through a carbon atom, or heterocycle bound through a carbon atom;
R 2 is H, C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 1-6 arlkyl, aryl, heteroaryl bound through a carbon atom, or heterocycle bound through a carbon atom;
R 3 to R 11 are, independently, H, CN, OH, NO 2 , N(R A ) 2 , halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 thioalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 1-6 arlkyl, aryl, heteroaryl, heterocycle, —OC(O)R A , —C(O)R A , C(O)OR A , —OC(O)N(R A ) 2 , —C(O)N(R A ) 2 , —N(R A )C(O)OR A , —N(R A )C(O)R A , —N(R A )C(O)N(R A ) 2 , —N(R A )S(O) 2 R A , —S(O)OR A , —S(O) 2 OR A , —S(O)N(R A ) 2 , —S(O) 2 N(R A ) 2 , or PO 3 (R A ) 2 ;
each R A is, independently, H, OH, C 1-6 alkyl, C 3-8 cycloalkyl, C 1-6 arlkyl, aryl, heteroaryl, or heterocycle;
or a pharmaceutically acceptable salt, solvate, or isomer thereof; wherein said agent is not tauroursodeoxycholic acid (TUDCA).
14. The method of claim 13 , wherein the SARS-CoV-2 is airborne.
15. The method of claim 13 , wherein the SARS-CoV-2 is on a surface.